Evidence map›Paper›PMID 24820173›Full record

ArticlePloS one2014

The use of Nanotrap particles technology in capturing HIV-1 virions and viral proteins from infected cells.

Elizabeth Jaworski, Mohammed Saifuddin, Gavin Sampey, Nazly Shafagati, Rachel Van Duyne, Sergey Iordanskiy, Kylene Kehn-Hall, Lance Liotta, Emanuel Petricoin, Mary Young and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Nonlytic Egress and Transmission in the Virus World.Annual review of biochemistry · 2025
    Review
  3. Article
  4. Article
  5. Comparison of NanotrapFrontiers in microbiology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021
    Review
  13. Article
  14. Review
  15. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Elizabeth JaworskiNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Mohammed SaifuddinNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Gavin SampeyNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Nazly ShafagatiNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Rachel Van DuyneNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America; Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.
Sergey IordanskiyNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Kylene Kehn-HallNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
Lance LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, United States of America.
Emanuel PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, United States of America.
Mary YoungDivision of Infectious Diseases, Georgetown University, Washington, District of Columbia, United States of America.
Benjamin LepeneCeres Nanosciences, Manassas, Virginia, United States of America.
Fatah KashanchiNational Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America.
George Mason University · USCeres Nanosciences · USGeorgetown University · USGeorge Washington University · US

Funding

Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVESR01AI043894 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KASHANCHI, FATAH · 1999 to 2015
$4.4M
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAsR01NS099029 · NINDS · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2016 to 2020
$1.9M
Structural Protein Networks ("Interactome") in HerpesvirusesR21AI070740 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ZHU, HENG · 2006 to 2007
$443k
NIAID NIH HHS AI070740NIAID NIH HHS R01 AI043894NIAID NIH HHS R21 AI070740NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS UO1-AI-31834NIAID NIH HHS UO1-AI-34989NIAID NIH HHS UO1-AI-34993NIAID NIH HHS UO1-AI-34994NIAID NIH HHS UO1-AI-35004NIAID NIH HHS UO1-AI-42590NICHD NIH HHS U01 HD032632NICHD NIH HHS UO1-HD-32632NINDS NIH HHS R01 NS099029
6 · The paper itself

Abstract

HIV-1 infection results in a chronic but incurable illness since long-term HAART can keep the virus to an undetectable level. However, discontinuation of therapy rapidly increases viral burden. Moreover, patients under HAART frequently develop various metabolic disorders and HIV-associated neuronal disease. Today, the main challenge of HIV-1 research is the elimination of the residual virus in infected individuals. The current HIV-1 diagnostics are largely comprised of serological and nucleic acid based technologies. Our goal is to integrate the nanotrap technology into a standard research tool that will allow sensitive detection of HIV-1 infection. This study demonstrates that majority of HIV-1 virions in culture supernatants and Tat/Nef proteins spiked in culture medium can be captured by nanotrap particles. To determine the binding affinities of different baits, we incubated target molecules with nanotrap particles at room temperature. After short sequestration, materials were either eluted or remained attached to nanotrap particles prior to analysis. The unique affinity baits of nanotrap particles preferentially bound HIV-1 materials while excluded albumin. A high level capture of Tat or Tat peptide by NT082 and NT084 particles was measured by western blot (WB). Intracellular Nef protein was captured by NT080, while membrane-associated Nef was captured by NT086 and also detected by WB. Selective capture of HIV-1 particles by NT073 and NT086 was measured by reverse transcriptase assay, while capture of infectious HIV-1 by these nanoparticles was demonstrated by functional transactivation in TZM-bl cells. We also demonstrated specific capture of HIV-1 particles and exosomes-containing TAR-RNA in patients' serum by NT086 and NT082 particles, respectively, using specific qRT-PCR. Collectively, our data indicate that certain types of nanotrap particles selectively capture specific HIV-1 molecules, and we propose to use this technology as a platform to enhance HIV-1 detection by concentrating viral proteins and infectious virions from infected samples.

Indexed as

Cell LineGene Products, tatHIV-1HIV InfectionsHumansNanoparticlesnef Gene Products, Human Immunodeficiency VirusViral ProteinsVirionGene Products, tatnef Gene Products, Human Immunodeficiency VirusViral Proteins

Identifiers

PMID24820173
PMCPMC4018389
OpenAlexW2038312349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.